Together, these results suggest that USP5 inhibition significantly enhances the efficacy of anti-CTLA-4 immunotherapy in vivo, which might be largely due to decreasing PD-1 and increasing cytotoxic activity of tumor-infiltrating CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.